Artiva Biotherapeutics stops AlloNK program, cuts 94% of staff and seeks strategic options

Artiva Biotherapeutics announced it will discontinue development of its AlloNK (AB‑101) cell therapy after two fatal safety events and longer‑term data showed insufficient durability of response. The company will lay off roughly 94% of its workforce and has engaged a financial adviser to explore options such as a sale, merger, licensing or liquidation. CEO Fred Aslan said the decision was based on an unfavorable risk‑benefit assessment and the need to protect patients.

The termination removes Artiva’s lead asset, eliminating future revenue potential from AlloNK and likely depresses the share price further. The cash balance of about $319.1 million gives the company liquidity to fund a wind‑down or any eventual transaction, but investors must assess the odds of a sale or liquidation delivering value.

  • 1Artiva will discontinue the AlloNK (AB‑101) program, ending all dosing in ongoing studies and canceling the planned Phase 3 pivotal trial.
  • 2Two Grade 5 (fatal) safety events were reported: one fatal leukoencephalopathy likely linked to fludarabine toxicity and a second sudden death deemed unrelated to the study drug.
  • 3The company plans to reduce its workforce by approximately 94%.
  • 4Artiva reported cash, cash equivalents and investments of roughly $319.1 million as of September 30, 2026.
  • 5The FDA requested that Artiva pause enrollment and dosing in the Phase 2a basket trial after the first fatal event.
  • 6Leerink Partners has been hired as financial advisor to evaluate strategic alternatives, which may include a merger, business combination, asset sale, licensing transaction or liquidation.

Sources